野村-格兰德制药(GLAD.NS):CDMO转型势头渐起,大型药企合作验证生产规模,指引2026-2030财年收入复合增速20%-CDMO pivot gaining traction;Large pharma partnership validates manufacturing scale;20% revenue CAGR guided over FY26-3-20260811【22页】

发表回复

后才能评论